223 related articles for article (PubMed ID: 28858867)
1. Pretreatment Serum Carbohydrate Antigen 19-9 Concentration Is a Predictor of Survival of Patients Who Have Undergone Curative Resection of Stage IV Rectal Cancer.
Miki H; Akiyoshi T; Ogura A; Nagasaki T; Konishi T; Fujimoto Y; Nagayama S; Noma H; Saiura A; Fukunaga Y; Ueno M
Dig Surg; 2018; 35(5):389-396. PubMed ID: 28858867
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of preoperatively elevated and postoperatively normalized carcinoembryonic antigen levels following curative resection of stage I-III rectal cancer.
Nakamura Y; Shida D; Tanabe T; Takamizawa Y; Imaizumi J; Ahiko Y; Sakamoto R; Moritani K; Tsukamoto S; Kanemitsu Y
Cancer Med; 2020 Jan; 9(2):653-662. PubMed ID: 31799750
[TBL] [Abstract][Full Text] [Related]
3. Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured?
Chen T; Zhang MG; Yu XJ; Liu L
Asian Pac J Cancer Prev; 2015; 16(2):661-6. PubMed ID: 25684504
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Significance of Preoperative Serum Carbohydrate Antigen 19-9 in Patients With Stage IV Colorectal Cancer.
Ozawa T; Ishihara S; Kawai K; Nozawa H; Yamaguchi H; Kitayama J; Watanabe T
Clin Colorectal Cancer; 2016 Dec; 15(4):e157-e163. PubMed ID: 27245559
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of carbohydrate antigen 19-9 in patients undergoing resection of biliary tract cancer.
Yamashita S; Passot G; Aloia TA; Chun YS; Javle M; Lee JE; Vauthey JN; Conrad C
Br J Surg; 2017 Feb; 104(3):267-277. PubMed ID: 28052308
[TBL] [Abstract][Full Text] [Related]
6. [Multivariate prognostic analysis of patients with low and middle rectal cancer after curative resection].
Li CS; Wan DS; Pan ZZ; Zhou ZW; Chen G; Wu XJ; Li LR; Lu ZH; Ding PR; Li Y
Ai Zheng; 2006 May; 25(5):587-90. PubMed ID: 16687079
[TBL] [Abstract][Full Text] [Related]
7. An elevated preoperative serum carbohydrate antigen 19-9 level is a significant predictor for peritoneal dissemination and poor survival in colorectal cancer.
Takakura Y; Ikeda S; Imaoka Y; Urushihara T; Itamoto T
Colorectal Dis; 2015 May; 17(5):417-25. PubMed ID: 25512077
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of apical lymph node metastasis in patients with node-positive rectal cancer.
Peng J; Wu H; Li X; Sheng W; Huang D; Guan Z; Wang M; Cai S
Colorectal Dis; 2013 Jan; 15(1):e13-20. PubMed ID: 23057847
[TBL] [Abstract][Full Text] [Related]
9. Preoperative Tumor Markers Independently Predict Survival in Stage III Gastric Cancer Patients: Should We Include Tumor Markers in AJCC Staging?
Lin JX; Wang W; Lin JP; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Lin M; Tu R; Zheng CH; Huang CM; Zhou ZW; Li P
Ann Surg Oncol; 2018 Sep; 25(9):2703-2712. PubMed ID: 29971670
[TBL] [Abstract][Full Text] [Related]
10. Predictors for regional lymph node metastasis in T1 rectal cancer: a population-based SEER analysis.
Brunner W; Widmann B; Marti L; Tarantino I; Schmied BM; Warschkow R
Surg Endosc; 2016 Oct; 30(10):4405-15. PubMed ID: 26895892
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of preoperative carcinoembryonic antigen/tumor size in rectal cancer.
Cai D; Huang ZH; Yu HC; Wang XL; Bai LL; Tang GN; Peng SY; Li YJ; Huang MJ; Cao GW; Wang JP; Luo YX
World J Gastroenterol; 2019 Sep; 25(33):4945-4958. PubMed ID: 31543685
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of carcinoembryonic antigen and carbohydrate antigen 19-9 in stage IV colorectal cancer patients after R0 resection.
Abe S; Kawai K; Ishihara S; Nozawa H; Hata K; Kiyomatsu T; Tanaka T; Watanabe T
J Surg Res; 2016 Oct; 205(2):384-392. PubMed ID: 27664887
[TBL] [Abstract][Full Text] [Related]
13. Predictors of long-term survival in patients with stage IV colorectal cancer with multi-organ metastases: a single-center retrospective analysis.
Miyamoto Y; Hayashi N; Sakamoto Y; Ohuchi M; Tokunagam R; Kurashige J; Hiyoshi Y; Baba Y; Iwagami S; Yoshida N; Yoshida M; Baba H
Int J Clin Oncol; 2015 Dec; 20(6):1140-6. PubMed ID: 25947545
[TBL] [Abstract][Full Text] [Related]
14. Preoperative serum level of CA19-9 predicts recurrence after curative surgery in node-negative colorectal cancer patients.
Nakagoe T; Sawai T; Tsuji T; Jibiki MA; Nanashima A; Yamaguchi H; Yasutake T; Ayabe H; Arisawa K
Hepatogastroenterology; 2003; 50(51):696-9. PubMed ID: 12828063
[TBL] [Abstract][Full Text] [Related]
15. Intersphincteric resection for very low rectal adenocarcinoma: univariate and multivariate analyses of risk factors for recurrence.
Akasu T; Takawa M; Yamamoto S; Ishiguro S; Yamaguchi T; Fujita S; Moriya Y; Nakanishi Y
Ann Surg Oncol; 2008 Oct; 15(10):2668-76. PubMed ID: 18618181
[TBL] [Abstract][Full Text] [Related]
16. Elevated CA19-9 as the Most Significant Prognostic Factor in Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiotherapy.
Zhang LN; OuYang PY; Xiao WW; Yu X; You KY; Zeng ZF; Xu RH; Gao YH
Medicine (Baltimore); 2015 Nov; 94(45):e1793. PubMed ID: 26559251
[TBL] [Abstract][Full Text] [Related]
17. Prognostic effect of perioperative change of serum carcinoembryonic antigen level: a useful tool for detection of systemic recurrence in rectal cancer.
Park YA; Lee KY; Kim NK; Baik SH; Sohn SK; Cho CW
Ann Surg Oncol; 2006 May; 13(5):645-50. PubMed ID: 16538413
[TBL] [Abstract][Full Text] [Related]
18. Preoperative predictors for early recurrence of resectable pancreatic cancer.
Nishio K; Kimura K; Amano R; Yamazoe S; Ohrira G; Nakata B; Hirakawa K; Ohira M
World J Surg Oncol; 2017 Jan; 15(1):16. PubMed ID: 28069033
[TBL] [Abstract][Full Text] [Related]
19. Selective lateral pelvic lymph node dissection in patients with advanced low rectal cancer treated with preoperative chemoradiotherapy based on pretreatment imaging.
Akiyoshi T; Ueno M; Matsueda K; Konishi T; Fujimoto Y; Nagayama S; Fukunaga Y; Unno T; Kano A; Kuroyanagi H; Oya M; Yamaguchi T; Watanabe T; Muto T
Ann Surg Oncol; 2014 Jan; 21(1):189-96. PubMed ID: 23963871
[TBL] [Abstract][Full Text] [Related]
20. Predictive Early Recurrence Factors of Preoperative Clinicophysiological Findings in Pancreatic Cancer.
Suzuki S; Shimoda M; Shimazaki J; Maruyama T; Oshiro Y; Nishida K; Sahara Y; Nagakawa Y; Tsuchida A
Eur Surg Res; 2018; 59(5-6):329-338. PubMed ID: 30453288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
